Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia

Leukemia and Lymphoma

Volumn 38, Issue 3-4, 2000, Pages 309-315

  Feldman, Eric J ^a,b   Seiter, Karen ^a   Traganos, Frank ^a   Darzynkiewicz, Zbigniew ^a   Goff, Heather ^a   Pozzuoli, Monica ^a   Baskind, Paul ^a   Santos, Sarah ^a   Ahmed, Tauseef ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute leukemia; Cytarabine; Etoposide; High dose; Mitoxantrone; Myelogenous

Indexed keywords

ACICLOVIR; ANTIEMETIC AGENT; CD34 ANTIGEN; CIPROFLOXACIN; CYTARABINE; DIPHENHYDRAMINE; ETOPOSIDE; FLUCONAZOLE; METHYLPREDNISOLONE; MITOXANTRONE; SEROTONIN ANTAGONIST;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CYTOGENETICS; DIARRHEA; FEMALE; HEART DISEASE; HEART EJECTION FRACTION; HUMAN; HYPERBILIRUBINEMIA; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; SURVIVAL RATE; VOMITING;

EID: 0034024425     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009087021     Document Type: Article

References (17)

1. Mayer RJ, Davis RB, Schiffer CA, Berk DT, Powell BL, Schulman P, Omura GA, Moore JO, Mcintyre OR, Frei E, for the Cancer and Leukemia Group B: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896, 1994.
2. Bishop JS, Matthews JT, Young GA, Szer J, Gilett A, Joshua D, Bradock K, Enno A, Wolf MM, Fox R, Cobcroft R, Hermann R, Van Der Weyden M, Lowenthal RM, Page F, Garson M, Juneja S: A randomized trial of high-dose cytarabine in acute myeloid leukemia. Blood 87:1710, 1996.
3. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84:10 Suppl. 1, 111a (abstr).
4. Arlin Z, Case DC Jr, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K: Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177, 1990.
5. Alberts DS, Young L, Mason N, Salmon SE. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by peritoneal administration. Semin Oncol 12 (Suppl. 4):38, 1985.
6. Grant S. Arlin Z. Gewitz D, Feldman E: Effect of pharmacologically relevant concentration of mitoxantrone on the in vitro growth of leukemic blast progenitors. Leukemia 5: 336, 1991.
7. Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V, Mahoney ME: High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 82:3133, 1993.
8. Feldman EJ, Alberts D, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P: Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 11:2002, 1993.
9. Dixon WJ, Massey FJ Jr: Introduction to Statistical Analysis (ed. 4). New York, McGraw-Hill, 1983.
10. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966.
11. Machin D, Campbell MJ: Statistical Tables for the Design of Clinical Trials. Oxford, Blackwell Scientific Publications, 1987.
12. Damon LE, Rugo HS, Ries CA, Linker CA: Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia apr; 8(4) 535-41, 1994.
13. Yates JW, Wallace HJ, Ellison RR, Holland JF: Cytosine arabinoside (NSC-62878) and daunorubicin (NSC-83142) therapy in acute non-lymphocytic leukemia. Cancer Chemother Rep 57:485, 1973.
14. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J., Fishleder A, Miller M: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717, 1995.
15. Appelbaum FR, Dahlberg S, Thomas ED, Buckner CD, Cheever MA, Clift RA, Crowley J, Deeg HJ, Fefer A, Greenberg PD: Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med 101:581, 1984.
16. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Simon SR, Grever M: A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88:2841, 1996.
17. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O, Connell MJ: Varying intensity of postremission therapy in acute myeloid leukemia, Blood 79:1924, 1995.